CJC-1295 DAC vs Ipamorelin
A side-by-side research comparison of CJC-1295 DAC and Ipamorelin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | CJC-1295 DAC | Ipamorelin |
|---|---|---|
| Full name | CJC-1295 with Drug Affinity Complex | Ipamorelin (Selective GH Secretagogue) |
| Category | Growth Hormone | Growth Hormone |
| Status | Research compound | Research compound |
| Mechanism | The DAC moiety binds serum albumin creating a depot that slowly releases active CJC-1295 for continuous GHRH signaling. | Selectively activates GHSR on pituitary somatotrophs. Unlike GHRP-6 and hexarelin, does not significantly activate ACTH or prolactin-releasing pathways. |
| Molecular weight | 3,647 Da | 711.9 Da |
| Half-life | 8 days | 2 hours |
| Bioavailability | High (SubQ) | High (SubQ) |
| Typical dose | 2 mg | 100-300 mcg |
| Frequency | 1-2x per week | 1-3x daily |
| Route | Subcutaneous | Subcutaneous injection |
CJC-1295 DAC reported benefits
- Once/twice weekly dosing
- Sustained IGF-1 elevation
- Convenient schedule
- Long-term body composition changes
Ipamorelin reported benefits
- Clean GH release
- No cortisol or prolactin increase
- Improved sleep
- Fat loss
- Joint support
- Anti-aging benefits
Related comparisons
Research and educational reference only. Not medical advice.